LMP1 induces the phenotypic transformation of fibroblasts and affects regulators of the cell cycle during this process. LMP1 decreases expression of the cyclin-dependent kinase inhibitor p27 and increases the levels and phosphorylation of cyclin-dependent kinase 2 and the retinoblastoma protein. In the present study, the effects of LMP1 on cell cycle progression and the mechanism of p27 downregulation by LMP1 were determined. Although p27 is frequently regulated at the posttranscriptional level during cell cycle progression and in cancer, LMP1 did not decrease ectopically expressed p27. However, LMP1 did decrease p27 RNA levels and inhibited the activity of p27 promoter reporters. The LMP1-regulated promoter element was mapped to a region containing two E2F sites. Electrophoretic mobility shift assays determined that the regulated cis element bound an inhibitory E2F complex containing E2F4 and p130. These findings indicate that LMP1 decreases p27 transcription through effects on E2F family transcription factors. This property likely contributes to the ability of LMP1 to stimulate cell cycle progression.
Epstein-Barr virus (EBV) is a herpesvirus that causes infectious mononucleosis and is associated with a number of malignancies. EBV infection of B cells results in a latent infection and the transformation of B cells in vitro and in vivo.Several proteins are required for EBV-mediated B-cell transformation, including the EBV nuclear antigens (EBNAs), EBNA1, EBNA2, EBNA3A, and EBNA3C, and latent membrane protein 1 (LMP1). LMP1 is expressed in most EBV-associated cancers and is considered the EBV oncogene as it is able to induce fibroblast transformation (34,60,83,84). Expression of LMP1 is frequently detected in nasopharyngeal carcinoma, and LMP1 induces phenotypic changes in epithelial cells and nasopharyngeal carcinoma cell lines, including increased motility, invasion, and migration (12,45,60,66,73).LMP1 is a constitutively active tumor necrosis factor receptor homologue. The transmembrane domain of LMP1 mediates self-association in the absence of ligand, and LMP1 is recruited to cholesterol-rich lipid raft domains in the membrane (3,14,20,28,58,81). LMP1 initiates signaling from two carboxyl-terminal activating regions (CTAR1 and CTAR2) by recruiting tumor necrosis factor receptor-associated factors (TRAFs) and other adaptors (33). LMP1 induces constitutive signaling of nuclear factor B (NF-B), phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (11,16,31,43,44,52,56,61,71).Signaling from CTAR1 is required for EBV B-cell transformation and for LMP1 fibroblast transformation (5,30,32,53,78). CTAR1 uniquely activates several pathways and proteins and induces both canonical and noncanonical NF-B, PI3K, and MAPK signaling. Several growth-stimulating proteins upregulated by CTAR1 have been identified, including the epidermal growth factor receptor, TRAF1, and inhibitors of differentiation 1 (Id1) and Id3 (13,18,51). LMP1 induces the transcription of the epiderma...